Work

Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Year: 2019

Type: article

Abstract: Background: CC-90011 is a potent, selective, reversible oral inhibitor of the epigenetic target, lysine-specific demethylase 1A (LSD1) that has demonstrated anti-proliferative activity against cancer cells in vitro and in patient-derived xenograft models.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz029

Authors: A. Hollebecque, J.S. de Bono, R. Plummer, N. Isambert, P. Martin-Romano, E. Baudin, S. Mora, E. Filvaroff, M. Lamba, Z. Nikolova

Institutions: Institut Gustave Roussy, Institute of Cancer Research, Centre Georges François Leclerc, Celgene (United States)

Language: English

Topic: Epigenetics and DNA Methylation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,250

OpenAlex ID: W2898359511

FWCI: 0.912

Cites:

Cited by: 13

Related to: 10